New launch from AristaMD increases wound care and dermatology consult support by facilitating seamless eConsult image transfer

October 10, 2019

Upload photos to an eConsult photo app via your mobile device for your dermatology consult.

AristaMD’s eConsult Photo App strengthens the platform’s ability to provide seamless wound care and dermatology consult support, improving access to care for patients in need of timely care

SAN DIEGO – Oct. 10, 2019 – AristaMD, an innovative telehealth platform that delivers primary care providers timely and documented specialist insight, announced today the launch of an app allowing its providers to easily transfer images as part of the eConsult platform. The new web-based AristaMD Photo App is an easy-to-access, streamlined, and HIPAA-compliant solution that further enhances electronic consultation efficiency and effectiveness for cases needing visual references—most commonly the dermatology consult.

AristaMD, which launched in 2013, aims to improve healthcare outcomes by connecting its thousands of participating payers and providers to specialists through eConsults. It is already proven to deliver cost-effective, more timely access to specialty care. Providers simply use their mobile phone to take photos through the app, which are automatically and securely saved exclusively to the AristaMD platform, then continue to process their referral order and eConsult as usual.

There are fewer practicing dermatologists in rural regions. Geographic barriers compound the issue of long wait times for specialist appointments. “Since 2009, patient wait times for a dermatology appointment have increased by 46 percent, or from an average of 22.1 days to 32.3 days in 2017.” Timely access to care for dermatological issues can have a significant impact on patient health, as conditions include life-threatening and quickly progressing conditions such as skin cancer. Researchers have found “providing specialty treatment to a potential melanoma within 14 days of diagnosis could improve a patient’s prognosis by 20 percent.”

Use of AristaMD’s eConsults has proven highly effective with 81% of dermatology consults replacing a face-to-face visit with a dermatologist. The Photo App will continue improving patient access to this specialty care for even more case uses.

“Currently, patients are waiting anywhere from two to four months for a specialist appointment, but the reality is that a large portion of those specialist referrals are not needed,” said Brooke LeVasseur, CEO of AristaMD. “The new AristaMD Photo App will help PCPs continue to significantly reduce unnecessary face-to-face referrals in even more cases needing visual documentation. This marks one of many product innovations my team has been working on to expand the benefits of eConsults to as many patients as possible.”

For additional information on AristaMD’s Photo App, please visit

About AristaMD

eConsult solutions that improve quality of care

AristaMD is focused on improving patient outcomes through more timely access to specialty care. Its eConsult platform provides a telehealth solution that empowers primary care providers with clinical workup checklists and the ability to conduct electronic consults (also known as eConsults or virtual consults) to significantly improve the patient referral process and allow greater access to timely, high-quality care. Designed to seamlessly integrate into physician referral workflows, the platform allows payers and providers to quickly and cost-effectively launch specialist eConsults using their own specialists or those provided by AristaMD’s contracted panel of board-certified experts. AristaMD’s platform has proven to deliver cost-effective, timely access to specialty care through eConsults, significantly reducing the need for face-to-face visits while increasing patient satisfaction. Committed to driving better health outcomes, AristaMD partners with healthcare stakeholders to ensure their success in the transition to value-based care.

For additional information, visit:, or follow AristaMD on LinkedIn and Twitter.